Fludrocortisone Acetate Tablets
Failed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.
354 recalls, newest first
Failed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.
Marketed without an approved NDA/ANDA: FDA analysis found product to be tainted with undeclared acetaminophen, diclofenac, and phenylbutazone.
Labeling: Incorrect or Missing Lot and/or Exp Date. Missing lot number and expiration dates on packets
Failed Dissolution Specifications
Subpotent drug: The potency of the active (menthol) was less than the label claim of 4%.
Subpotent drug: The potency of the active (menthol) was less than the label claim of 4%.
Subpotent drug: The potency of the active (menthol) was less than the label claim of 4%.
Subpotent drug: The potency of the active (menthol) was less than the label claim of 4%.
Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.
Failed Dissolution Specifications; the product is dissolving faster than the specified limits.
Sub-potent Drug
CGMP deviations
CGMP deviations
CGMP deviations
CGMP deviations
CGMP deviations
CGMP deviations
CGMP deviations
CGMP deviations
This product is being recalled due to the tube weld failure presents itself as a slow leak and can be difficult to detect.
Lack of Assurance of Sterility: Potential presence of leaks originating from the Connector Assembly component.
Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C
Microbial Contamination of Non-Sterile Products: confirmed presence of mold contamination
Failed Impurities/Degradation Specifications: Related Substances
Subpotent Drug